Menu Search
Equities

Zelira Therapeutics Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
G1G:STU

Zelira Therapeutics Ltd

Actions
  • Price (EUR)0.344
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change+13.91%
  • Beta1.0830
Data delayed at least 15 minutes, as of Feb 11 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Zelira Therapeutics Limited is an Australia-based biopharmaceutical company. The Company is engaged in the research, development and commercialization of clinically validated cannabinoid-based medicines. It owns a portfolio of products and a pipeline of candidates undergoing clinical development positioned to enter global markets. It is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription (Rx) business for the treatment of a variety of medical conditions, including insomnia, autism and chronic non-cancer pain, as well as offering over the counter (OTC) products. It has two medications: HOPE and ZENIVOL. ZENIVOL is a cannabinoid-based medicine for the treatment of chronic insomnia. The Company in partnership with SprinJeneCBD, introduced a full line of oral care products, including SprinJeneCBD toothpaste product, which is a hemp-derived, oral care products containing cannabinoids, blackseed oil and zinc utilizing patented technology.

  • Revenue in AUD (TTM)660.00
  • Net income in AUD-3.63m
  • Incorporated2003
  • Employees8.00
  • Location
    Zelira Therapeutics LtdLevel 3, 101 St Georges TerracePERTH 6000AustraliaAUS
  • Phone+61 86558-0886
  • Fax+61 86316-3337
  • Websitehttps://zeliratx.com/home/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.